Lilly partners with Haya for lncRNA obesity target deal worth $1bn
Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.
Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.
What's Your Reaction?
